Developmental and Epileptic Encephalopathy 42 (DEE42) Cell Models for Research

Developmental and Epileptic Encephalopathy 42 (DEE42) is a rare genetic disorder characterized by early-onset seizures, developmental delay, and intellectual disability. The exact prevalence is unknown, but it is estimated to affect a small fraction of the population. According to the World Health Organization (WHO), epilepsy affects over 50 million people worldwide, with a significant proportion having genetic causes. DEE42 is caused by mutations in the SCN1A gene, which encodes the alpha subunit of the voltage-gated sodium channel NaV1.1. The condition typically presents in infancy with seizures that are often refractory to treatment. The clinical impact is severe, with most patients experiencing profound neurodevelopmental impairment. There is no cure, and current treatments focus on seizure management and supportive care. The 5-year survival rate is not well-defined due to the rarity, but mortality is higher than in the general population, often due to sudden unexpected death in epilepsy (SUDEP). Research into DEE42 is critical for understanding the pathophysiology and developing targeted therapies.

DEE42 is an ideal model for studying the molecular mechanisms of epilepsy and neurodevelopment. The disease is monogenic, with clear genotype-phenotype correlations, making it amenable to gene editing. Public datasets, such as those from the NCBI Gene and ClinVar, provide extensive information on SCN1A mutations. Open questions include the precise effects of different mutations on channel function, the role of SCN1A in inhibitory interneuron excitability, and the potential for gene therapy. Gene-edited cell models, such as induced pluripotent stem cell (iPSC)-derived neurons and isogenic cell lines, are valuable tools for investigating these questions and for drug screening.

The primary pathogenic mechanism in DEE42 is haploinsufficiency or dominant-negative effects of SCN1A mutations, leading to reduced sodium current in inhibitory interneurons. This results in network hyperexcitability and seizures. Key pathways include:

• • Voltage-gated sodium channel function: SCN1A encodes NaV1.1, which is critical for action potential generation in GABAergic interneurons.
• • GABAergic signaling: Reduced interneuron excitability leads to decreased GABA release, disrupting the excitation-inhibition balance.
• • Neuronal network synchronization: Impaired inhibitory control leads to hypersynchronous firing and seizure activity.

These pathways are interconnected and contribute to the epileptic phenotype.

Data from ClinVar and COSMIC. Note that SCN1A is the most frequently mutated gene in DEE42.

The main deregulated networks in DEE42 include:

• • Voltage-gated sodium channel complex: SCN1A, SCN1B, and other subunits.
• • GABAergic synapse: GABRA1, GABRG2, and associated proteins.
• • Potassium channel signaling: KCNQ2/KCNQ3 heteromers.
• • Calcium signaling: CACNA1A and other voltage-gated calcium channels.

These networks are critical for neuronal excitability and synaptic transmission. Dysregulation leads to hyperexcitability and seizure susceptibility.

Organoids offer a 3D model that recapitulates brain development and network activity, making them valuable for studying DEE42.

• • PDX models: Not commonly used for DEE42 due to the neurological nature.
• • GEMMs: Knock-in mice with SCN1A mutations (e.g., R1648H) recapitulate seizure phenotypes.
• • Induced models: Conditional knockout mice using Cre-lox systems to delete SCN1A in specific neuronal populations.
• • Zebrafish models: Used for high-throughput drug screening.

These models are essential for studying disease mechanisms and testing therapies.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific SCN1A mutations. For example, a knockout line with a frameshift mutation in SCN1A can model haploinsufficiency, while a knock-in line with a missense mutation (e.g., p.Thr875Met) can model dominant-negative effects. These models are commercially available and sequence-verified, ensuring reproducibility. They are used for drug screening, functional studies, and understanding genotype-phenotype correlations. Isogenic pairs (mutant vs. wild-type) allow for direct comparison, reducing variability.

Knockout and knock-in lines are used to validate the role of SCN1A in neuronal excitability. For example, CRISPR knockout of SCN1A in iPSC-derived neurons reduces sodium current and increases network bursting. Knock-in of a patient-specific mutation can recapitulate the disease phenotype. These models are also used to identify modifier genes through genetic screens.

Isogenic cell lines are used in high-throughput screening to identify compounds that rescue the mutant phenotype. For example, a screen for drugs that increase sodium current in SCN1A knockout neurons may identify potential therapies. Resistance to antiepileptic drugs can be modeled by exposing cells to increasing concentrations and selecting for resistant clones.

CRISPR synthetic lethality screens can identify genes that are essential in SCN1A mutant cells but not wild-type, providing potential therapeutic targets. For example, a screen may reveal that certain potassium channel blockers are selectively toxic to mutant cells, suggesting a new treatment approach.